Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 25;24(12):2093–2106. doi: 10.1093/neuonc/noac107

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 3 — Increased expression of cancer testis antigens leads to increased CTL activation and killing in a TCR-MHC dependent fashion. Relative expression of (A) NY-ESO, (D) SSX2 and (G) PRAME to GAPDH as measured by RTqPCR. Expression is represented as 2^–∆∆CT and statistical significance as calculated by paired two-tailed student t test. Activation of (B) NY-ESO, (E) SSX2 and (H) PRAME specific CTL as measured by TNFα+/CD107a+ cells by flow cytometry. All cells pregated on CD3+/CD8+ population. (C) NY-ESO, (F) SSX2 and (I) PRAME specific CTL mediated killing as measured by LDH release against primary cell lines. Data shown are from biological triplicates representative of a minimum of 3 independent experiments. Ab—W6/32 MHC class I blocking antibody. Statistical significance as calculated by 2-way ANOVA. * P < .05, ** P < .01, *** P < .001, **** P < .0001.

Fig. 3 — Increased expression of cancer testis antigens leads to increased CTL activation and killing in a TCR-MHC dependent fashion. Relative expression of (A) NY-ESO, (D) SSX2 and (G) PRAME to GAPDH as measured by RTqPCR. Expression is represented as 2^–∆∆CT and statistical significance as calculated by paired two-tailed student t test. Activation of (B) NY-ESO, (E) SSX2 and (H) PRAME specific CTL as measured by TNFα+/CD107a+ cells by flow cytometry. All cells pregated on CD3+/CD8+ population. (C) NY-ESO, (F) SSX2 and (I) PRAME specific CTL mediated killing as measured by LDH release against primary cell lines. Data shown are from biological triplicates representative of a minimum of 3 independent experiments. Ab—W6/32 MHC class I blocking antibody. Statistical significance as calculated by 2-way ANOVA. * P < .05, ** P < .01, *** P < .001, **** P < .0001.